Patents by Inventor Maximilien Murone
Maximilien Murone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230338347Abstract: The present invention relates to new uses and dosage regimens of inhibitors of the Notch signalling pathway such as 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine for the treatment of tumours.Type: ApplicationFiled: September 16, 2021Publication date: October 26, 2023Inventors: Michael Bauer, Rajwinder Lehal, Maximilien Murone, Pavel Pisa, Florian Vogl, Maria Bobadilla
-
Patent number: 8962637Abstract: The present invention relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. The compounds of the present invention are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the STAT3 activation and therefore abnormal growth of particular cell types. Notably, the compounds of the present invention are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3.Type: GrantFiled: January 14, 2013Date of Patent: February 24, 2015Assignees: Debiopharm S.A., Aurigene Discovery Technologies Ltd.Inventors: Andrès Mc Allister, Maximilien Murone, Saumitra Sengupta, Shankar Jayaram Shetty
-
Patent number: 8609821Abstract: The invention relates to antibodies directed against APRIL (A Proliferation Inducing TNF Ligand, also known as TALL-2), in particular the monoclonal antibody Aprily-2, hybridoma cells producing monoclonal antibody Aprily-2, and the use of a combination of an antibody against membrane-anchored APRIL and Aprily-2 in the diagnosis of B cell lymphoma resistance to treatment and the prognosis of clinical development of Diffuse Large B-Cell (DLBCL) lymphoma from high risk patients (>60 years and International Prognostic Index >2). An amino acid sequence GTGGPSQNGEGYP called Stalk, useful in the preparation of antibodies, is described.Type: GrantFiled: September 22, 2006Date of Patent: December 17, 2013Assignee: Enzo Therapeutics, Inc.Inventors: Bertrand Huard, Lars French, Olivier Donze, Maximilien Murone
-
Publication number: 20130143895Abstract: The present invention relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. The compounds of the present invention are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the STAT3 activation and therefore abnormal growth of particular cell types. Notably, the compounds of the present invention are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3.Type: ApplicationFiled: January 14, 2013Publication date: June 6, 2013Inventors: Andrès Mc Allister, Maximilien Murone, Saumitra Sengupta, Shankar Jayaram Shetty
-
Patent number: 8440679Abstract: The present invention relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. The compounds of the present invention are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the STAT3 activation and therefore abnormal growth of particular cell types. Notably, the compounds of the present invention are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3.Type: GrantFiled: February 17, 2011Date of Patent: May 14, 2013Assignees: Debiopharm S.A., Aurigene Discovery Technologies LtdInventors: Andrès Mc Allister, Maximilien Murone, Saumitra Sengupta, Shankar Jayaram Shetty
-
Patent number: 8394939Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, immunoadhesins, agonists and antagonists (including antibodies) to human & vertebrate fused.Type: GrantFiled: September 29, 2006Date of Patent: March 12, 2013Assignee: Genentech, Inc.Inventors: Frederic de Sauvage, Arnon Rosenthal, Maximilien Murone
-
Publication number: 20130012518Abstract: The present invention relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. The compounds of the present invention are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the STAT3 activation and therefore abnormal growth of particular cell types. Notably, the compounds of the present invention are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3.Type: ApplicationFiled: February 17, 2011Publication date: January 10, 2013Applicants: Aurigene Discovery Technologies Ltd., Debiopharm S.A.Inventors: Andrès Mc Allister, Maximilien Murone, Saumitra Sengupta, Shankar Jayaram Shetty
-
Publication number: 20110143367Abstract: The invention relates to antibodies directed against APRIL (A Proliferation Inducing TNF Ligand, also known as TALL-2), in particular the monoclonal antibody Aprily-2, hybridoma cells producing monoclonal antibody Aprily-2, and the use of a combination of an antibody against membrane-anchored APRIL and Aprily-2 in the diagnosis of B cell lymphoma resistance to treatment and the prognosis of clinical development of Diffuse Large B-Cell (DLBCL) lymphoma from high risk patients (>60 years and International Prognostic Index >2). An amino acid sequence GTGGPSQNGEGYP called Stalk, useful in the preparation of antibodies, is described.Type: ApplicationFiled: September 22, 2006Publication date: June 16, 2011Applicants: APOTECH CORPORATION, UNIVERSITY OF GENEVAInventors: Bertrand Huard, Lars French, Olivier Donzé, Maximilien Murone
-
Patent number: 7579161Abstract: The present invention is directed to novel polypeptides having homology to a polypeptide suppressor of the Drosophila melanogaster fused protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: April 1, 2005Date of Patent: August 25, 2009Assignee: Genentech, Inc.Inventors: Frederic J. de Sauvage, Maximilien Murone, Arnon Rosenthal, Donna M. Stone, Austin L. Gurney, William I. Wood
-
Patent number: 7259245Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, immunoadhesins, agonists and antagonists (including antibodies) to human & vertebrate fused.Type: GrantFiled: June 17, 2002Date of Patent: August 21, 2007Assignee: Genentech, Inc.Inventors: Frederic de Sauvage, Arnon Rosenthal, Maximilien Murone
-
Publication number: 20070042415Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, immunoadhesins, agonists and antagonists (including antibodies) to human & vertebrate fused.Type: ApplicationFiled: September 29, 2006Publication date: February 22, 2007Inventors: Frederic de Sauvage, Arnon Rosenthal, Maximilien Murone
-
Patent number: 7144996Abstract: The present invention is directed to novel polypeptides having homology to a polypeptide suppressor of the Drosophila melanogaster fused protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: March 2, 2000Date of Patent: December 5, 2006Assignee: Genentech, Inc.Inventors: Frederic J. de Sauvage, Maximilien Murone, Arnon Rosenthal, Donna M. Stone, Austin L. Gurney, William I. Wood
-
Publication number: 20050196814Abstract: The present invention is directed to novel polypeptides having homology to a polypeptide suppressor of the Drosophila melanogaster fused protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: ApplicationFiled: April 1, 2005Publication date: September 8, 2005Inventors: Frederic de Sauvage, Maximilien Murone, Arnon Rosenthal, Donna Stone, Austin Gurney, William Wood
-
Publication number: 20040102610Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, immunoadhesins, agonists and antagonists (including antibodies) to human & vertebrate fused.Type: ApplicationFiled: June 17, 2002Publication date: May 27, 2004Applicant: Genentech, Inc.Inventors: Frederic de Sauvage, Arnon Rosenthal, Maximilien Murone
-
Patent number: 6451977Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptide, vectors and host cells expressing, immunoadhesins, agonists and antagonists to human & vertebrate fused.Type: GrantFiled: September 3, 1999Date of Patent: September 17, 2002Assignee: Genentech, Inc.Inventors: Frederic de Sauvage, Arnon Rosenthal, Maximilien Murone